✉news ScienceBiology first seen 3 d ago, last 21 min ago, peak #1
Private equity turns to bioconvergence investing
Original: Investing in the age of bioconvergence
Private equity is turning its attention to bioconvergence, the growing overlap between biology, technology and engineering that is producing new areas for investment. A new discussion in the buyouts world examines how firms are approaching opportunities that combine life sciences with fields like computing, materials and automation, and what this shift means for portfolio strategy and returns.
Why now: Investors are increasingly looking at the intersection of biology and technology as a new frontier for capital, prompting fresh analysis in the private equity press.
private equitybioconvergenceBuyoutsPEI Private Equity
Rank over time, top of the chart is #1. 23 snapshots from 3 d ago to 21 min ago.
Evidence
- Investing in the age of bioconvergence · PEI Private Equity
- Investing in the age of bioconvergence · Buyouts
API: https://socialmediatrends-api.osmike.com/v1/trends/3262210